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Abstract Obesity is an established risk factor for post-
menopausal breast cancer in the general population.
However, it is still unclear whether this association also
exists in BRCA1/2 mutation carriers. We investigated the
association between self-reported anthropometric measures
and breast cancer risk in a nationwide retrospective cohort
study, including 719 BRCA1/2 carriers, of whom 218 had
been diagnosed with breast cancer within 10 years prior to
questionnaire completion. All time-varying Cox propor-
tional hazards analyses were stratified by menopausal
status. For premenopausal breast cancer, no statistically
significant associations were observed for any of the
anthropometric measures. The association between body
mass index (BMI) at age 18 and premenopausal breast
cancer risk suggested a trend of decreasing risk with
increasing BMI (HR22.50–24.99 vs. 18.50–22.49 = 0.83, 95%
CI = 0.47–1.44 and HRC25.00 vs. 18.50–22.49 = 0.41, 95%
CI = 0.13–1.27). For postmenopausal breast cancer, being
1.67 m and taller increased the risk 1.7-fold (HR = 1.67,
95% CI = 1.01–2.74) when compared to a height
\1.67 m. Compared with a current body weight\72 kg, a
current body weight of C72 kg increased the risk of post-
menopausal breast cancer 2.1-fold (95% CI = 1.23–3.59).
A current BMI of C25.0 kg/m2, an adult weight gain of
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5 kg or more, and a relative adult weight gain of 20% or
more were all non-significantly associated with a 50–60%
increased risk of postmenopausal breast cancer [HR =
1.46 (0.86–2.51), HR = 1.56 (95% CI = 0.85–2.87), and
HR = 1.60 (95% CI = 0.97–2.63), respectively], when
compared with having a healthy or stable weight. No
associations for body weight or BMI at age 18 were
observed. In conclusion, menopausal status seemed to
modify the association between body weight and breast
cancer risk among BRCA1/2 carriers. We observed no
clear association between body weight and premenopausal
breast cancer, while overweight and weight gain increased
postmenopausal breast cancer risk. Carriers may reduce
their risk of postmenopausal breast cancer by maintaining a
healthy body weight throughout life.
Keywords Body weight  Breast cancer  BRCA1/2 
HEBON  Epidemiology
Introduction
The estimated lifetime risk of developing breast cancer for
BRCA1/2 mutation carriers (carriers) varies between 30
and 80% [1–6]. Reasons for variation may include different
mutations in the same gene (allelic variation) [5, 7–9], the
effect of modifying genes [10–12], and non-genetic mod-
ifiers [13]. Several studies have indicated that the pene-
trance of BRCA1 and BRCA2 mutations has increased in
recent generations [14–16], which supports the concept that
non-genetic risk factors, of which the prevalence has
increased, also affect the risk. Overweight might be such a
risk factor, because its prevalence has gradually increased
over the last decades [17]. Menopausal status has been
shown to modify the association between overweight and
breast cancer risk in the general population [17]. In the
general population, overweight and obesity or, more spe-
cifically, adult weight gain are established risk factors for
postmenopausal breast cancer [18, 19]. In contrast, over-
weight and obesity may reduce the risk of premenopausal
breast cancer [18, 19].
Few studies examined the effects of body weight and/or
weight change on breast cancer risk in BRCA1/2 mutation
carriers. Three relatively small studies showed inconsistent
results [15, 20, 21]. The large study by Kotsopoulos et al.
[22] was the only study examining menopausal status as a
potential effect modifier of the association between body
weight and breast cancer risk among BRCA1/2 mutation
carriers. No associations were found.
The aim of the present study was to assess whether dif-
ferent anthropometric measures, i.e. height, body weight,
body mass index (BMI) and body weight change throughout
life, affected the risk of pre- and postmenopausal breast
cancer in a large population of BRCA1/2 mutation carriers,
while adjusting for physical activity.
Materials and methods
Study population
The present study was conducted within the framework of
the HEBON study, of which the design was described
earlier [23]. In brief, the HEBON study is an ongoing
nationwide retrospective cohort study with prospective
follow-up among members of BRCA1/2 families in the
Netherlands. The total study population of the present
study consisted of 1,390 female BRCA1/2 mutation carri-
ers who were approached to participate in the HEBON
study in the period January 1999 through August 2007.
Two hundred and seventy-eight carriers refused to partic-
ipate or did not respond. Finally, the study population for
the present study consisted of 1,112 BRCA1/2 mutation
carriers (n = 1,112/1,390; response 80%). We excluded
seven carriers of whom the age at end of follow-up was
missing. BRCA1/2 mutation carriers of whom at least 50%
of the information on anthropometric measures was miss-
ing were excluded (n = 125). The study population for the
analyses consisted of 980 carriers, among whom 38 (4%)
obligate carriers (women who were not tested themselves
but considered as carrier because at least two first degree
relatives were proven carriers, i.e. one of their children plus
one of their parents or brothers or sisters). Five percent
(n = 49; response 76%) of the questionnaires was com-
pleted by a proxy, because the woman herself had died.
This was equivalent to 76% completed by a proxy among
obligate carriers (n = 29/38).
Analytic cohort
Previous studies showed that excess body weight (defined
as overweight (BMI between 25.0 and 29.9 kg/m2) or
obesity (BMI C 30.0 kg/m2) decreases overall survival
[18, 24–26] and breast cancer-specific survival [17, 27–29].
The association between obesity and poor prognosis of
breast cancer was present in both pre- and postmenopausal
carriers. To reduce (potential) survival bias, we restricted
the analysis to person-years within 10 years prior to
questionnaire completion [23, 30–32]. We excluded cases
who died a long time ago whose prognosis might have been
influenced by BMI. Therefore, the final ‘analytic’ cohort
consists of 719 carriers. In total, 218 cases were diagnosed
with breast cancer within the 10-year period in 4,992
person-years.
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Assessment of anthropometric measures
Carriers were asked to report their height (m), exact body
weight at age 18 (kg) and exact body weight (kg) at the
time of questionnaire completion. Cases were also asked to
report their exact body weight in the year prior to their
breast cancer diagnosis. Additionally, for different age
periods, carriers were asked to complete a grid with body
weight in 5 kg categories (i.e. \55, 55–59, 60–64, 65–69,
70–74, 75–79, 80–84, 85–89, 90–94, [94 kg) from age
18 years onwards in 10-year age periods (i.e. 20–29,
30–39, 40–49, 50–59, 60–69, 70? years), excluding peri-
ods of pregnancy. Body weight at age 18 and height were
used to calculate BMI at age 18. Height, body weight at age
18 and BMI at age 18 were analyzed as fixed variables.
Current body weight was calculated for each year (i.e. from
age 18 until time of censoring) with the use of the grid with
body weight and where an exact value of body weight was
available this value was used [i.e. body weight at diagnosis
(n = 218 cases) and body weight at questionnaire com-
pletion for unaffected carriers who were censored at time
of questionnaire completion (n = 29)]. Current body
weight and BMI, adult weight change (calculated as the
difference between the age-specific body weight and at age
18), and relative adult weight change (calculated as the
adult weight change divided by body weight at age 18),
changed over time and were therefore determined for each
age (year) of observation and included as time-varying
variables.
Statistical analysis
The adjusted hazard ratios (HRs) as estimates of relative
risk and 95% confidence intervals (95% CI) were obtained
using a time-varying, multivariate Cox proportional haz-
ards model with age (in years) as time scale. Follow-up
started at 10 years prior to questionnaire completion and
ended at date of first breast cancer diagnosis (n = 218),
date of bilateral prophylactic mastectomy (n = 195), date
of linkage with Netherlands Pathology Database (PALGA)
and the Netherlands cancer registry (NCR) (n = 257), date
of completing the questionnaire if no informed consent for
linkage was given (n = 29), or date of death (n = 20),
whichever occurred first. All analyses were adjusted for
age at the start of follow-up, intrinsically stratified for birth
cohort (B1945, 1946–1955, 1956–1964, C1965) and gene
(BRCA1 and BRCA2) and clustered on family to correct
for potential within family correlations in risk factors.
Because menopausal status has been shown to modify
the association between overweight and breast cancer risk
in the general population [17], all analyses were stratified
according to menopausal status. Carriers were considered
postmenopausal 12 months after their last menstrual period
(age of menopause). Forty-two percent of carriers in the
analytic cohort (299/719) were postmenopausal at the end
of follow-up. For these 299 women, age at menopause was
the censoring event, while it was the starting age within the
postmenopausal cohort. Additionally, for the premeno-
pausal cohort all analyses were weighted according to the
weighted cohort approach to correct for potential testing
bias [33]. Unfortunately, for the postmenopausal cohort it
was not possible to conduct weighted analyses as the power
was too low to create stable cohort- specific weights.
For the premenopausal cohort (n = 609 among which
155 cases in 3,013 person-years), height, body weight at
age 18, current body weight, adult weight change, and
relative adult weight change were categorized based on the
distribution of the total cohort at the end of follow-up. For
the postmenopausal cohort (n = 299 among whom 63
cases in 1,979 person-years), dichotomized variables based
on the median values were created because of the smaller
numbers. For both cohorts, BMI at age 18 and current BMI
were categorized according to the World Health Organi-
zation [34].
For the multivariate models, stepwise forward con-
founder selection was performed, evaluating the effect of
adding one confounder at a time, based on a more than
10% change in (at least one of) the HRs of the main
exposure variables under investigation, i.e. current BMI
and adult weight change. The carriers with a healthy and/or
stable weight were considered as the reference group.
Confounders (categorized based on the distribution of the
entire cohort (n = 980) at the end of follow-up) were:
lifetime sports activity (never sports activity, \11.0,
11.0–22.7,[22.7 mean MET-h/week; time-varying) for the
premenopausal cohort, and parity (nulliparae, 1–2 children,
C3 children), type of menopause and use of hormonal
replacement therapy (HRT) [natural menopause and never
HRT use; natural menopause and ever HRT use; bilateral
prophylactic (salpingo)oophorectomy (BPSO) and never
HRT use; BPSO and ever HRT use; surgical (ovarian
cancer) and never HRT use], and lifetime sports activity
(never sports activity,\11.0, 11.0–22.7,[22.7 mean MET-
h/week; time-varying) for the postmenopausal cohort. Age
at menarche, oral contraceptive use, age at first full-term
pregnancy, breast-feeding, smoking, alcohol consumption,
and family history did not change the HRs by more than
10% and were omitted from our final models. No violation
of the proportional hazards assumption by any of the
confounding variables or by current BMI and adult weight
change was observed.
Two-sided p values B0.05 were considered statistically
significant. All analyses were performed using STATA/SE
10.0 (StataCorp LP).
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Results
The mean ages at end of follow-up in the premenopausal
and postmenopausal cohorts were 38.9 ± 7.9 and 54.9 ±
11.4 years, respectively. In both cohorts, cases were older
than non-cases at end of follow-up (premenopausal
44.0 ± 8.1 and 41.5 ± 9.9 years, respectively, p = 0.002;
postmenopausal 61.1 ± 8.7 and 53.4 ± 11.8 years, respec-
tively, p \ 0.001; proxy data excluded). In general, the
characteristics of the premenopausal cases were reasonably
similar to the non-cases (Table 1). However, in the post-
menopausal cohort there were some differences, for
example, cases were born earlier, more often had a positive
family history, and had less children than non-cases. Forty-
three percent of postmenopausal carriers had experienced a
natural menopause, while 57% had a menopause that was
surgically induced (48 and 9% by BPSO and ovarian cancer
diagnosis, respectively). Furthermore, in the postmeno-
pausal cohort, cases had more often experienced a natural
menopause (75%) than non-cases (35%). Twenty percent of
postmenopausal carriers had ever used HRT.
The median body weight at age 18 was 58 kg for both
cohorts. Because the median height was somewhat larger
for premenopausal carriers than for postmenopausal carri-
ers (median 1.69 and 1.65 m, respectively; data not
shown), the median BMI at age 18 was slightly lower
among premenopausal carriers than in postmenopausal
carriers (20.4 vs. 21.2 kg/m2; data not shown). The median
current body weight and adult weight change were also
lower in the premenopausal cohort than in the postmeno-
pausal cohort (65 and 5 kg weight gain vs. 70 and 10 kg
weight gain, respectively; data not shown). Approximately
one-third of the premenopausal carriers and half of the
postmenopausal carriers were overweight (C25.00 kg/m2)
at the end of follow-up.
For premenopausal breast cancer, no statistically sig-
nificant associations were observed for any of the anthro-
pometric measures (Table 2). The association between BMI
at age 18 and premenopausal breast cancer risk suggested a
trend of decreasing risk with increasing BMI (HR = 0.83,
95% CI = 0.47–1.44 and HR = 0.41, 95% CI = 0.13–1.27
for 22.50–24.99 kg/m2 and C25.00 kg/m2 when compared
with 18.50–22.49 kg/m2, respectively). When compared to
a current body weight of 58–62 kg, both a low current
weight (HRB57 kg = 1.52, 95% CI = 0.84–2.78) and a high
current weight (HRC68 = 1.35, 95% CI = 0.74–2.47) were
non-significantly associated with an increased premeno-
pausal breast cancer risk. A trend of decreasing premeno-
pausal breast cancer risk with increasing current BMI was
suggested (HR = 0.87, 95% CI = 0.53–1.42 and HR =
0.75, 95% CI = 0.43–1.31 for 22.50–24.99 kg/m2 and
C25.00 kg/m2 when compared with 18.50–22.49 kg/m2,
respectively). We found no association between adult
weight change and relative weight change with risk of
premenopausal breast cancer. Analyses restricted to
BRCA1 carriers showed very similar results compared to all
carriers combined (data not shown).
For the postmenopausal cohort, it was not possible to
conduct weighted analyses as the power was too low to
create stable cohort-specific weights. Therefore, the pre-
sented unweighted estimates (Table 3) might be slightly
biased toward unity. Being 1.67 m and taller increased the
risk of postmenopausal breast cancer 1.7-fold (HR = 1.67,
95% CI = 1.01–2.74) when compared with a height
\1.67 m. We observed no associations for body weight or
BMI at age 18 with postmenopausal breast cancer risk.
When compared to a current body weight below 72 kg,
weighing 72 kg or more increased the risk of postmeno-
pausal breast cancer 2.1-fold (HR = 2.10, 95% CI =
1.23–3.59). A current BMI of C25.00 kg/m2, an adult
weight gain of 5 kg or more, and a relative adult weight
gain of 20% or more were all non-significantly associated
with a 1.5–1.6-fold increased risk of postmenopausal breast
cancer [HR = 1.46 (0.86–2.51), HR = 1.56 (95% CI =
0.85–2.87), and HR = 1.60 (95% CI = 0.97–2.63), respec-
tively] when compared with having a healthy or stable body
weight.
Discussion
The results of our study on the effect of body weight and
weight change on breast cancer risk among BRCA1/2
mutation carriers are generally in line with the literature
based on the general population, where menopausal status
is a clear effect modifier of the association with body
weight. For premenopausal breast cancer, no statistically
significant associations were observed with any of the
anthropometric measures. If any, we observed a decreasing
risk of premenopausal breast cancer with increasing BMI at
age 18. Among postmenopausal women, we observed that
height, current overweight, and increased relative weight
change were all associated with an increased postmeno-
pausal breast cancer risk. In the present study, all observed
associations were independent of the effect of physical
activity.
So far, few studies examined the effects of anthropo-
metric measures on breast cancer risk in BRCA1/2 muta-
tion carriers, with inconsistent results. The largest study on
the association between body weight and breast cancer risk
in carriers was a study among 1,073 case–control pairs by
Kotsopoulos et al. [22]. They focused on changes in body
weight and observed that a loss of at least 10 lb between
ages 18 and 30 years was associated with a decreased
risk of breast cancer at ages 30–40. We did not observe
an association between adult weight loss and risk of
196 Breast Cancer Res Treat (2011) 126:193–202
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Table 1 Characteristics of the study population (n = 719) by menopausal status
Characteristic Premenopausal cohort (n = 609) Postmenopausal cohort (n = 299)
Total Cases Total Cases
No.a % No.a % No.a % No.a %
Gene
BRCA1 468 77 120 77 223 76 50 79
BRCA2 141 23 35 23 76 24 13 21
Proxy data
No 601 99 151 97 289 97 61 97
Yes 8 1 4 3 10 3 2 3
Birth cohort
B1945 26 4 3 2 109 36 42 67
1946–1955 137 23 45 29 96 32 17 27
1956–1964 207 34 65 42 68 23 3 5
C1965 239 39 42 27 26 9 1 1
Age at end of follow-up
B34 years 185 30 49 32 5 2 1 2
35–40 years 167 27 41 26 16 5 1 2
41–49 years 186 31 52 34 82 27 7 11
C50 years 71 12 13 8 196 66 54 86
Lifetime sports activity
Never 218 36 53 34 138 46 35 55
\11.0 MET-h/week 195 32 43 28 72 24 8 13
11.0–22.7 MET-h/week 175 29 52 34 66 22 12 19
C22.7 MET-h/week 21 3 7 4 23 8 8 13
Family history
No 269 45 63 41 120 41 15 25
Yes 324 55 91 59 171 59 46 75
Age at menarche
B12 years 207 34 56 36 83 28 21 33
13 years 152 25 36 24 75 25 13 21
C14 years 244 41 62 40 139 47 29 46
Parity
Nulliparous 185 30 43 28 49 16 7 11
Parous 424 70 112 72 250 84 56 89
Number of children
1–2 children 313 74 88 79 153 61 41 73
C3 children 111 26 24 21 97 39 15 27
Age at first full-term pregnancy
B22 years 74 17 22 20 66 26 13 23
23–25 years 87 21 24 21 67 27 15 27
26–27 years 67 16 15 13 48 19 15 27
C28 years 196 46 51 46 69 28 13 23
Breastfeeding
Never 106 25 29 26 62 25 14 25
Ever 317 75 82 74 188 75 42 75
Oral contraceptive use
Never 39 6 10 7 58 19 13 21
Ever 569 94 144 93 241 81 50 79
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premenopausal breast cancer, but numbers in our weight
loss category were small. The study of Kotsopoulos et al.
was intrinsically stratified on menopausal status of the
cases, but it is not quite clear how the menopausal status of
the controls was taken into account. The authors reported
that no effect modification of menopausal status was
present. The other studies in BRCA1/2 mutation carriers
did not adjust for or stratify on menopausal status, which
hampers the comparison with our results. In a case-only
study among 104 carriers, a healthy body weight at men-
arche and a lighter body weight at age 21 were associated
with a significant delay in the age at onset of breast cancer;
however, it is not clear whether these findings were
adjusted for birth cohort [15]. Similar to our observation of
increased postmenopausal breast cancer risk after adult
weight gain, Nkondjock et al. [21] observed a trend of
increased breast cancer risk with increasing weight gain
since age 18 and age 30. This effect was independent of
physical activity and energy intake. Chang-Claude et al.
[20] observed no association between BMI and breast
cancer risk in carriers. However, the two last studies were
relatively small and body weight might not always apply to
the prediagnostic period for cases and similar age ranges
for the unaffected. For women diagnosed with breast can-
cer, it has been shown that they frequently gain body
weight after diagnosis [35].
The present study has some strong and weak points that
should be considered in the interpretation of the results.
The primary strengths of our study include the large sam-
ple size, the detailed lifetime information on various
anthropometric measures, stratification by menopausal
status, adjustment for lifetime physical activity (time-
varying) and other confounders and the possibility to
cluster on family. In addition, we used the weighted cohort
approach for the premenopausal cohort [33]. However, the
retrospective character of the present study, the type of
study population, consisting of carriers tested in the clinical
setting, and the lack of weighting in the postmenopausal
cohort may have caused some biases in our results, which
are discussed below.
The association between obesity and poor overall sur-
vival [18, 24–26] or prognosis of breast cancer [17, 27–29],
might, if also true for BRCA1/2 carriers, have influenced
our study results. The inclusion of prevalent cases, may
have led toward bias to the null, overweight/obese pre-
valent cases may have been underrepresented because they
had died prior to study entry [24, 27, 28]. We reduced this
potential survival bias by restricting the analyses to person-
years within 10 years prior to questionnaire completion. In
general, the difference in HRs between the entire cohort,
starting follow-up at birth, and the analytic cohort indeed
suggested that survival bias might be present in our entire
cohort [e.g. the HR for adult weight change and the risk of
postmenopausal breast cancer in the entire cohort was 1.33
(95% CI = 0.80–2.22; data not shown) and 1.56 (95%
CI = 0.85–2.87) in the analytic cohort]. Although the
effect was small, we cannot exclude the presence of some
survival bias in our analytic cohort, because overweight/
obese BRCA1/2 carriers with early onset breast cancer and
a poor prognosis may not have survived 10 years to
Table 1 continued
Characteristic Premenopausal cohort (n = 609) Postmenopausal cohort (n = 299)
Total Cases Total Cases
No.a % No.a % No.a % No.a %
Type of menopause and HRT use
Natural and never HRT use 106 35 42 67
Natural and ever HRT use NA NA NA NA 23 8 5 8
Surgical, prophylactic and never HRT use 83 28 5 8
Surgical, prophylactic and ever HRT use 60 20 9 14
Surgical, ovarian cancer and never HRT use 27 9 2 3
Alcohol consumption
Never 235 39 69 45 116 39 21 33
Ever 374 61 86 55 183 61 42 67
Smoking
Never 270 44 74 48 132 44 28 45
Ever 339 56 81 52 166 56 34 55
NA not applicable
a Numbers do not always add up to 100% due to missing values; number of children, age at first full-term pregnancy and breastfeeding apply to
parous carriers only (100%); type of menopause and HRT use applies to postmenopausal carriers only (100%)
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participate in our study. Furthermore, we had a priori tried
to reduce potential survival bias by including proxy data
for obligate carriers who had died before study entry.
However, a large proportion (67%) of these questionnaires
had to be excluded because at least 50% of information on
anthropometric measures was missing, and as a result in the
analytic cohort only 2% of the questionnaires was com-
pleted by a proxy (n = 14/719).
A second limitation is the use of self-reported anthro-
pometric data. Although self-reported and objective
weights are correlated [19], studies on the validity of self-
reported anthropometric measures show consistent under-
reporting of self-reported body weight and overreporting of
height, especially among overweight and obese individuals
[19, 36]. We are not aware of studies that examined
potential differential misclassification according to breast
cancer case–control status. However, if we assume that
misclassification is non-differential, the systematic under-
reporting of obesity might have resulted in an overesti-
mated risk for a specific category.
In the general population, the increased postmenopausal
breast cancer risk observed in obese women is generally
Table 2 Anthropometric
measures and risk of
premenopausal breast cancer
a A time-varying Cox
proportional hazards model,
stratified for genes (BRCA1 and
BRCA2) and birth cohort
(B1945, 1946–1955,
1956–1964, C1965), clustered
on family (326 clusters), and
adjusted for lifetime sports
activity (mean MET-h/week in
active period; time-varying)
b Weighted cohort approach [33]
c Reference category
Person-years Cases Multivariate HR
(95% CI)
unweighteda
Multivariate HR
(95% CI)
weightedb
Height (m)
B1.64 537 32 0.84 (0.53–1.36) 0.73 (0.39–1.38)
1.65–1.68c 796 43 1.00 1.00
1.69–1.72 690 36 1.20 (0.76–1.89) 1.36 (0.75–2.47)
C1.73 990 44 0.99 (0.76–1.89) 0.89 (0.46–1.71)
Body weight at age 18 (kg)
B53 500 26 1.16 (0.70–1.93) 1.02 (0.53–1.97)
54–57c 688 39 1.00 1.00
57–60 791 46 1.26 (0.79–2.02) 1.01 (0.52–1.95)
C61 1,034 44 1.04 (0.64–1.70) 0.94 (0.50–1.78)
BMI at age 18 (kg/m2)
B18.49 544 28 0.84 (0.55–1.28) 0.72 (0.41–1.27)
18.50–22.49c 1,785 101 1.00 1.00
22.50–24.99 421 19 0.89 (0.57–1.38) 0.83 (0.47–1.44)
C25.00 263 7 0.73 (0.31–1.75) 0.41 (0.13–1.27)
Current body weight (kg)
B57 554 42 1.42 (0.88–2.30) 1.52 (0.84–2.78)
58–62c 592 24 1.00 1.00
63–67 521 25 0.88 (0.52–1.51) 0.92 (0.48–1.76)
C68 1,346 64 1.40 (0.87–2.25) 1.35 (0.74–2.47)
Current BMI (kg/m2)
B18.49 83 3 0.47 (0.14–1.60) 0.41 (0.09–1.85)
18.50–22.49c 1,334 63 1.00 1.00
22.50–24.99 786 48 0.98 (0.68–1.44) 0.87 (0.53–1.42)
C25.00 810 41 1.05 (0.68–1.61) 0.75 (0.43–1.31)
Adult weight change (kg)
C5 kg weight loss 170 9 1.00 (0.51–1.95) 1.03 (0.45–2.37)
\5 kg weight loss and \5 kg weight gainc 1,091 48 1.00 1.00
C5 kg and \10 kg weight gain 637 28 0.62 (0.38–1.01) 0.67 (0.37–1.21)
C10 kg and \15 kg weight gain 512 33 1.29 (0.78–2.12) 1.02 (0.56–1.86)
C15 kg weight gain 603 37 0.96 (0.59–1.56) 0.77 (0.41–1.45)
Relative weight change
B3.9% 869 38 0.99 (0.61–1.60) 0.85 (0.47–1.53)
4% and \13%c 799 39 1.00 1.00
13% and \25% 725 39 1.01 (0.65–1.57) 0.75 (0.42–1.34)
C25% 620 39 1.10 (0.71–1.72) 0.85 (0.48–1.51)
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explained by the higher rates of conversion of androgenic
precursors to estradiol through increased aromatase enzyme
activity in adipose tissue [18]. The reduced risk of breast
cancer after a BPSO in BRCA1/2 carriers [37] suggests that
hormonal influences are important in carriers, despite the
fact that the majority of BRCA1 associated breast cancers
have negative estrogen receptor status [38]. In vitro studies
indicate that estrogens may play a role in BRCA1-related
carcinogenesis [39] and suggest that BRCA1 may function as
part of a feedback mechanism to regulate estrogen signaling
[40]. Subgroup analysis of the association between anthro-
pometric measures and breast cancer risk among premeno-
pausal BRCA1 carriers showed similar results as in the total
analytic premenopausal cohort. BRCA2-associated breast
tumors tend to be similar to sporadic cases. A subgroup
analysis among BRCA2 carriers was not possible due to lack
of power.
The results of our study on the effect of height on breast
cancer risk among BRCA1/2 mutation carriers are gener-
ally in line with the literature based on the general popu-
lation, where height is an independent factor that has been
shown to have a modest contribution to the development of
postmenopausal breast cancer [41, 42], whereas in pre-
menopausal women the relation is less clear and not sig-
nificant [42]. Potential biological mechanisms include
among others childhood energy intake plus related growth
hormone release and increased levels of insulin-like growth
factor [43–45], childhood physical activity [46], and
number of ductal stem cells that develop in the breast in
utero [47].
Previous studies in the general population showed that
HRT use interacts with obesity in the development of
postmenopausal breast cancer, probably by sharing hor-
monal carcinogenic pathways [42, 48]. However, in the
Netherlands HRT has not been widely used by postmeno-
pausal carriers (see Table 1 and [49]). The results of
multivariate analyses restricted to never users were not
markedly different, e.g. the HRs for current body weight
and the risk of postmenopausal breast cancer in the total
analytic postmenopausal cohort (HR = 2.10, 95% CI =
1.23–3.59) and the cohort of never users (HR = 2.05, 95%
CI = 1.10–3.82; data not shown) were quite similar. In the
present study, we adjusted our analysis for HRT use as it
proved to be a confounder, but the power was too low to
test whether interaction was present.
In conclusion, the results of the present study indicate
that there was no clear association between any of the
anthropometric measures and premenopausal breast cancer
risk in BRCA1/2 mutation carriers. For postmenopausal
breast cancer risk, we observed associations similar to what
is observed in the general population, i.e. overweight and
adult weight gain increased the risk of postmenopausal
breast cancer in BRCA1/2 carriers. Body weight is one of
the few non-genetic modifiers for breast cancer. Carriers
Table 3 Anthropometric
measures and risk of
postmenopausal breast cancer
a A time-varying Cox
proportional hazards model,
stratified for genes (BRCA1 and
BRCA2) and birth cohort
(B1945, 1946–1955,
1956–1964, C1965), clustered
on family (185 clusters), and
adjusted for parity (nulliparae,
1–2 children, [2 children), type
of menopause and HRT use
[natural menopause and never
HRT use, natural menopause
and ever HRT use, BPSO and
never HRT use, BPSO and ever
HRT use, surgical (ovarian
cancer) and never HRT use] and
lifetime sports activity (mean
MET-h/week in active period;
time-varying)
b Reference category
Person-years Cases Multivariate HR
(95% CI) unweighteda
Height (m)
\1.67b 1,589 35 1.00
C1.67 1,333 28 1.67 (1.01–2.74)
Body weight at age 18 (kg)
\58b 1,146 20 1.00
C58 1,776 43 1.18 (0.62–2.23)
BMI at age 18 (kg/m2)
\22.50b 2,157 42 1.00
C22.50 765 21 0.94 (0.37–2.39)
Current body weight (kg)
\72b 1,764 29 1.00
C72 1,158 34 2.10 (1.23–3.59)
Current BMI (kg/m2)
\25.00b 1,608 27 1.00
C25.00 1,314 36 1.46 (0.86–2.51)
Adult weight change (kg)
\5 kg weight gainb 695 14 1.00
C5 kg weight gain 2,227 49 1.56 (0.85–2.87)
Relative adult weight change
\20%b 1,520 31 1.00
C20% 1,402 32 1.60 (0.97–2.63)
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may reduce postmenopausal breast cancer risk by main-
taining a healthy body weight throughout life. Our findings
require confirmation by future studies focusing on pro-
spective follow-up in larger sample sizes and other coun-
tries. Future research should also focus on the potential
interaction between body weight, physical activity and
lifestyle/behavioral determinants of adult weight change
for BRCA1/2 mutation carriers.
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